Assessment of Biv1-Coviran Inactivated Vaccine–Elicited Neutralizing Antibody Against the Emerging Sars-Cov-2 Variants of Concern

Assessment of Biv1-Coviran Inactivated Vaccine–Elicited Neutralizing Antibody Against the Emerging Sars-Cov-2 Variants of Concern Publisher Pubmed

Salehi M¹ ; Hosseini H² ; Jamshidi HR³ ; Jalili H⁴ ; Tabarsi P⁵ ; Mohraz M⁶ ; Karimi H⁷ ; Lotfinia M⁸ ; Aalizadeh R⁹ ; Mohammadi M¹⁰ ; Ramazi S¹¹ ; Abdoli A^{7, 12}

Source: Clinical Microbiology and Infection Published:2022

Abstract

Objectives: The BIV1-CovIran vaccine is highly effective against COVID-19. The neutralizing potency of all SARS-CoV-2 vaccines seems to be decreased against variants of concern. We assessed the sensitivity of the Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants to neutralizing antibodies (NAbs) present in sera from individuals who had received the BIV1-CovIran candidate vaccine compared with an original Wuhan-related strain. Methods: The ability of vaccine serum to neutralize the variants was measured using the conventional virus neutralization test. The correlation of spike (S) protein antibody and anti-receptor binding domain with neutralizing activity was investigated. Results: The current study demonstrated that 29 of 32 (90.6%; 95% CI: 75.0–98.0) of the vaccinees developed NAbs against a Wuhan-related strain. It is noteworthy that 28 (87.50%) and 24 of 32 (75%) of the recipients were able to produce NAbs against Alpha, Beta, and Delta variants, respectively. Serum virus-neutralizing titres for different SARS-CoV-2 strains were weakly correlated with anti–receptor binding domain antibodies (Spearman r = 36-42, p < 0.05), but not S-binding antibodies (p > 0.05). Discussion: Although there was a reduction in neutralization titres against the Alpha, Beta, and Delta variants compared with the Wuhan strain, BIV1-CovIran still exhibited potent neutralizing activity against the SARS-CoV-2 variants of concern. © 2022 European Society of Clinical Microbiology and Infectious Diseases

Related Docs

View other Related Docs

1. A Comparison Between Sars-Cov-1 and Sars-Cov2: An Update on Current Covid-19 Vaccines, DARU# Journal of Pharmaceutical Sciences (2022)

2. Evaluation of Response to Different Covid-19 Vaccines in Vaccinated Healthcare Workers in a Single Center in Iran, Journal of Medical Virology (2022)

3. Enhancement of Immunogenicity and Neutralizing Responses Against Sars-Cov-2 Spike Protein Using the Fc Fusion Fragment, Life Sciences (2023)

Experts (# of related papers)

View all Related Experts

Amirhasan Zarnani (3)

Mohammad Mehdi Amiri (3)

Style	Citing Format
MLA	Salehi M, et al.. "Assessment of Biv1-Coviran Inactivated Vaccine–Elicited Neutralizing Antibody Against the Emerging Sars-Cov-2 Variants of Concern." Clinical Microbiology and Infection, vol. 28, no. 6, 2022, pp. 882.e1-882.e7.
APA	Salehi M, Hosseini H, Jamshidi HR, Jalili H, Tabarsi P, Mohraz M, Karimi H, Lotfinia M, Aalizadeh R, Mohammadi M, Ramazi S, Abdoli A (2022). Assessment of Biv1-Coviran Inactivated Vaccine–Elicited Neutralizing Antibody Against the Emerging Sars-Cov-2 Variants of Concern. Clinical Microbiology and Infection, 28(6), 882.e1-882.e7.
Chicago	Salehi M, Hosseini H, Jamshidi HR, Jalili H, Tabarsi P, Mohraz M, Karimi H, et al.. "Assessment of Biv1-Coviran Inactivated Vaccine–Elicited Neutralizing Antibody Against the Emerging Sars-Cov-2 Variants of Concern." Clinical Microbiology and Infection 28, no. 6 (2022): 882.e1-882.e7.
Harvard	Salehi M et al. (2022) 'Assessment of Biv1-Coviran Inactivated Vaccine–Elicited Neutralizing Antibody Against the Emerging Sars-Cov-2 Variants of Concern', Clinical Microbiology and Infection, 28(6), pp. 882.e1-882.e7.
Vancouver	Salehi M, Hosseini H, Jamshidi HR, Jalili H, Tabarsi P, Mohraz M, et al.. Assessment of Biv1-Coviran Inactivated Vaccine–Elicited Neutralizing Antibody Against the Emerging Sars-Cov-2 Variants of Concern. Clinical Microbiology and Infection. 2022;28(6):882.e1-882.e7.
BibTex	@article{ author = {Salehi M and Hosseini H and Jamshidi HR and Jalili H and Tabarsi P and Mohraz M and Karimi H and Lotfinia M and Aalizadeh R and Mohammadi M and Ramazi S and Abdoli A}, title = {Assessment of Biv1-Coviran Inactivated Vaccine–Elicited Neutralizing Antibody Against the Emerging Sars-Cov-2 Variants of Concern}, journal = {Clinical Microbiology and Infection}, volume = {28}, number = {6}, pages = {882.e1-882.e7}, year = {2022} }
RIS	TY - JOUR AU - Salehi M AU - Hosseini H AU - Jamshidi HR AU - Jalili H AU - Tabarsi P AU - Mohraz M AU - Karimi H AU - Lotfinia M AU - Aalizadeh R AU - Mohammadi M AU - Ramazi S AU - Abdoli A TI - Assessment of Biv1-Coviran Inactivated Vaccine–Elicited Neutralizing Antibody Against the Emerging Sars-Cov-2 Variants of Concern JO - Clinical Microbiology and Infection VL - 28 IS - 6 SP - 882.e1 EP - 882.e7 PY - 2022 ER -

Science Communicator Platform

Authors

Abstract